This paper considers a fast track to non-energy applications of nuclear fusion that is associated with the ‘fusion for neutrons’ (F4N) paradigm. Being a useful product accompanying energy, fusion neutrons are more valuable than the energy released in DT reactions and they are urgently needed for research purposes and to develop and validate modern technologies. In the near future neutron yield in fusion devices will become significantly larger than that of fission and accelerator sources. This paper describes a compact tokamak fusion neutron source based on a small spherical tokamak (FNS-ST) with a MW range of DT fusion power and considers the key physics issues of this device. The major and minor radii are ∼0.5 and ∼0.3 m with magnetic field ∼1.5 T, heating power less than 15 MW and plasma current 1–2 MA. The production rate of DT neutrons of (3–10) × 1017 n s−1 and their flux at the first wall of 0.2 MW m−2 ensure that the device is capable of fusion–fission demonstration experiments. The problems of major concern are discharge initiation, current drive, plasma—fast ion beam stability and high first wall and divertor loads. The conceptual design provides solutions to these problems and suggests the feasibility of the FNS-ST.

No abstract

Psychopharmacological treatment has been the mainstay in long-term maintenance of bipolar disorder (BD) patients for the last 60 years. Conventionally accepted treatment options are primarily based on expert opinion rather than on well-executed, independently funded research. Investigation of maintaining patients without medications using treatment alternatives has been neglected. This clinical case series examines the outcomes of 7 BD patients who experienced a poor response or significant side effects with conventional treatment modalities. Patients were gradually and safely withdrawn from all medications. Treatment strategies were based on an individualized holistic approach using herbs, nutritional supplements, vitamins, amino acids, acupuncture, dietary recommendations, and behavioral modifications. Multiple treatment modalities were combined addressing the etiological causes for BD symptoms. Upon withdrawal from psychotropic medications, patients were free of medication-induced side effects and obtained psychiatric stability for at least 10 months. Further research is needed to investigate the long-term outcomes of BD treatment modalities based on well-defined successful outcome criteria, such as reduction in symptoms, improvement in quality of life, overall health outcomes, and cost effectiveness.

No abstract

No abstract